Mind Medicine (MindMed) (NASDAQ:MNMD) Trading Down 3.8% on Insider Selling

Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) fell 3.8% during mid-day trading on Tuesday following insider selling activity. The stock traded as low as $12.92 and last traded at $12.95. 547,743 shares were traded during trading, a decline of 66% from the average session volume of 1,612,456 shares. The stock had previously closed at $13.46.

Specifically, insider Mark Sullivan sold 11,276 shares of the business’s stock in a transaction on Friday, December 26th. The shares were sold at an average price of $13.15, for a total transaction of $148,279.40. Following the completion of the transaction, the insider directly owned 282,576 shares in the company, valued at $3,715,874.40. The trade was a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Robert Barrow sold 25,791 shares of Mind Medicine (MindMed) stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total transaction of $339,151.65. Following the completion of the sale, the chief executive officer owned 778,477 shares in the company, valued at approximately $10,236,972.55. This trade represents a 3.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In other Mind Medicine (MindMed) news, insider Daniel Karlin sold 5,600 shares of the stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $73,640.00. Following the completion of the sale, the insider owned 425,025 shares in the company, valued at approximately $5,589,078.75. This represents a 1.30% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Analyst Upgrades and Downgrades

MNMD has been the subject of several recent analyst reports. Jones Trading initiated coverage on shares of Mind Medicine (MindMed) in a research report on Tuesday, December 23rd. They set a “buy” rating and a $61.00 price objective for the company. Canaccord Genuity Group lifted their price target on shares of Mind Medicine (MindMed) from $16.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Chardan Capital upgraded Mind Medicine (MindMed) to a “strong-buy” rating in a research note on Wednesday, November 19th. Royal Bank Of Canada lowered their price target on shares of Mind Medicine (MindMed) from $21.00 to $20.00 and set an “outperform” rating for the company in a report on Friday, November 7th. Finally, Needham & Company LLC set a $28.00 target price on Mind Medicine (MindMed) and gave the stock a “buy” rating in a research report on Monday, October 13th. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $30.33.

Key Stores Impacting Mind Medicine (MindMed)

Here are the key news stories impacting Mind Medicine (MindMed) this week:

• Positive Sentiment: MM-120 moved into Phase III for GAD and MDD, with pivotal readouts expected in 2026 — a clear near-term clinical catalyst that underpins upside expectations for revenue potential and valuation. Read More.
• Positive Sentiment: Analyst coverage has turned supportive recently (e.g., JonesTrading initiation with a buy and high target), helping lift sentiment and providing potential upside via higher price targets. Read More.
• Neutral Sentiment: Institutional ownership (~28%) and a wide mix of analyst ratings (consensus “Buy” but varied targets) are supportive but produce mixed conviction; this can moderate moves as larger holders rebalance. Read More.
• Negative Sentiment: Clustered insider selling reported on Dec. 26: CEO Robert Barrow sold 25,791 shares, Mark Sullivan sold 11,276 shares and Daniel Karlin sold 5,600 shares — these disclosures can create near-term selling pressure or signal liquidity-taking by insiders. Read More.

Mind Medicine (MindMed) Price Performance

The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.30 and a current ratio of 3.30. The stock has a market capitalization of $1.28 billion, a P/E ratio of -6.36 and a beta of 2.57. The stock has a 50-day simple moving average of $12.33 and a 200 day simple moving average of $10.47.

Mind Medicine (MindMed) (NASDAQ:MNMD) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.26). On average, equities analysts forecast that Mind Medicine will post -1.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in MNMD. Marshall Wace LLP grew its holdings in shares of Mind Medicine (MindMed) by 31.9% during the 2nd quarter. Marshall Wace LLP now owns 3,421,224 shares of the company’s stock valued at $22,204,000 after purchasing an additional 828,067 shares during the last quarter. Wellington Management Group LLP lifted its position in Mind Medicine (MindMed) by 16.2% during the first quarter. Wellington Management Group LLP now owns 225,928 shares of the company’s stock valued at $1,322,000 after purchasing an additional 31,437 shares during the period. Geode Capital Management LLC increased its position in shares of Mind Medicine (MindMed) by 4.0% during the 2nd quarter. Geode Capital Management LLC now owns 1,733,454 shares of the company’s stock valued at $11,252,000 after purchasing an additional 66,663 shares during the last quarter. Persistent Asset Partners Ltd bought a new position in Mind Medicine (MindMed) in the 2nd quarter worth $238,000. Finally, Ally Bridge Group NY LLC lifted its position in shares of Mind Medicine (MindMed) by 18.1% during the 1st quarter. Ally Bridge Group NY LLC now owns 390,143 shares of the company’s stock valued at $2,282,000 after buying an additional 59,868 shares in the last quarter. 27.91% of the stock is currently owned by institutional investors and hedge funds.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) is a clinical-stage biopharmaceutical company focused on developing psychedelic-inspired therapies to address a range of mental health and neurological disorders. The company applies traditional drug development techniques to molecules derived from psychedelic compounds, with an emphasis on safety, efficacy and scalable manufacturing. Its research and development activities span small-molecule analogues, novel formulations and digital therapeutics designed to enhance or support pharmacological interventions.

The company’s lead development programs include MM-120, an investigational low-dose LSD formulation intended for treatment of anxiety; MM-310, an ibogaine-derived non-hallucinogenic compound targeting opioid withdrawal and addiction; and MM-402, a proprietary 5-MeO-DMT receptor agonist for mood and stress-related indications.